PMID- 1529875
OWN - NLM
STAT- MEDLINE
DCOM- 19921022
LR  - 20220427
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 124
IP  - 4
DP  - 1992 Oct
TI  - Assessment of patient outcome with the Minnesota Living with Heart Failure 
      questionnaire: reliability and validity during a randomized, double-blind, 
      placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
PG  - 1017-25
AB  - To determine the reliability and validity of a patient outcome questionnaire for 
      chronic heart failure, a randomized, double-blind, placebo-controlled, 3-month 
      trial of pimobendan, an investigational medication with inotropic and vasodilator 
      activities, was performed. Evaluated were 198 ambulatory patients with primarily 
      New York Heart Association (NYHA) class III heart failure from 20 referral 
      centers. Baseline therapy included digoxin, diuretics and, in 80%, a converting 
      enzyme inhibitor. Oral pimobendan at 2.5 (n = 49), 5.0 (n = 51), or 10 (n = 49) 
      mg daily or matching placebo (n = 49) was administered. The Minnesota Living with 
      Heart Failure (LIhFE) questionnaire was a primary outcome measure, along with an 
      exercise test. Interitem correlations identified subgroups of questions 
      representing physical and emotional dimensions. Repeated baseline scores were 
      highly correlated (r = 0.93), as were the physical (r = 0.89) and emotional (r = 
      0.88) dimension scores. Placebo did not have a significant effect with median 
      (25th, 75th percentile) changes from baseline scores of 1 (-3, 5), 1 (-2, 3), and 
      0 (-1, 2), respectively (all p values greater than 0.10). The 5 mg dose 
      significantly improved the total score, 7.5 (0, 18; p = 0.01) and the physical 
      dimension, 4 (0, 8; p = 0.01), compared with placebo. Changes in the total (r = 
      0.33; p less than 0.01) and physical (r = 0.35; p less than 0.01) scores were 
      weakly related to changes in exercise times, but corresponded well with changes 
      in patients' ratings of dyspnea and fatigue.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Rector, T S
AU  - Rector TS
AD  - Cardiovascular Division, University of Minnesota Medical School, Minneapolis 
      55455.
FAU - Cohn, J N
AU  - Cohn JN
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Pyridazines)
RN  - 0 (Vasodilator Agents)
RN  - 34AP3BBP9T (pimobendan)
SB  - IM
MH  - Activities of Daily Living
MH  - *Attitude to Health
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*drug therapy/epidemiology/*psychology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care/*methods
MH  - Pyridazines/*therapeutic use
MH  - Reproducibility of Results
MH  - Surveys and Questionnaires
MH  - Vasodilator Agents/*therapeutic use
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
AID - 0002-8703(92)90986-6 [pii]
AID - 10.1016/0002-8703(92)90986-6 [doi]
PST - ppublish
SO  - Am Heart J. 1992 Oct;124(4):1017-25. doi: 10.1016/0002-8703(92)90986-6.